The first big real-world study of the Pfizer/BioNTech vaccine to be independently reviewed shows the shot is highly effective at preventing Covid-19, in a potentially landmark moment for countries desperate to end lockdowns and reopen economies.

The risk of illness from Covid-19 dropped 95.8% among people who received both shots of Pfizer’s vaccine, Israel’s Health Ministry said on Feb. 20.

Pfizer’s Covid-19 vaccine greatly reduces virus transmission, according to two Israeli studies, shedding light on one of the biggest questions of the global effort to quash the pandemic.

Israel’s largest healthcare provider reported a 94% drop in symptomatic Covid-19 infections among 600,000 people who received two doses of Pfizer’s vaccine in the country’s biggest study to date.

Global coronavirus cases surpassed 100 million on Jan. 27, according to a Reuters tally, as countries around the world struggle with new virus variants and vaccine shortfalls.

Countries across the globe shut their borders to Britain on Dec. 21 due to fears about a highly infectious new coronavirus strain, causing travel chaos and raising the prospect of food shortages days before Britain is set to leave the European Union.

The global coronavirus death toll surpassed 1 million according to a Reuters tally, a bleak statistic in a pandemic that has devastated the global economy, overloaded health systems and turned daily life upside down.

The United States recorded 41 new measles cases last week, bringing 2019’s total number of cases to 981 in the worst outbreak of the disease since 1992, federal health officials said.

Israel will invest nearly 1 billion shekels ($287 million) in a project to make data about the state of health of its population available to researchers and private companies, Prime Minister Benjamin Netanyahu said.

– Array to receive a $30 million up-front payment and up to $425 million in additional development and commercialization milestones, as well as robust double-digit royalties on future sales – – Array retains full commercialization rights to binimetinib and encorafenib in United States, Canada, Japan and Korea – -NEMO Phase 3 trial remains on-track for […]